Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan, A.R.; Touchard, S.; Leckey, C.; O'Hagan, C.; Nevado-Holgado, A.J.; Barkhof, F.; Bertram, L.; Blin, O.; Bos, I.; Dobricic, V.; Engelborghs, S.; Frisoni, G.; Frölich, L.; Gabel, S.; Johannsen, P.; Kettunen, P.; Kłoszewska, I.; Legido-Quigley, C.; Lleó, A.; Martinez-Lage, P.; Mecocci, P.; Meersmans, K.; Molinuevo, J.L.; Peyratout, G.; Popp, J.; Richardson, J.; Sala, I.; Scheltens, P.; Streffer, J.; Soininen, H.; Tainta-Cuezva, M.; Teunissen, C.; Tsolaki, M.; Vandenberghe, R.; Visser, P.J.; Vos, S.; Wahlund, L.O.; Wallin, A.; Westwood, S.; Zetterberg, H.; Lovestone, S.; Morgan, B.P.

doi:10.1016/j.jalz.2019.03.007

Inflammatory biomarkers in Alzheimer's disease plasma.

Détails

Télécharger: 31047856.pdf (1114.03 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0

ID Serval

serval:BIB_E5F2C092E354

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

Inflammatory biomarkers in Alzheimer's disease plasma.

Périodique

Alzheimer's & dementia

Auteur⸱e⸱s

Morgan A.R., Touchard S., Leckey C., O'Hagan C., Nevado-Holgado A.J., Barkhof F., Bertram L., Blin O., Bos I., Dobricic V., Engelborghs S., Frisoni G., Frölich L., Gabel S., Johannsen P., Kettunen P., Kłoszewska I., Legido-Quigley C., Lleó A., Martinez-Lage P., Mecocci P., Meersmans K., Molinuevo J.L., Peyratout G., Popp J., Richardson J., Sala I., Scheltens P., Streffer J., Soininen H., Tainta-Cuezva M., Teunissen C., Tsolaki M., Vandenberghe R., Visser P.J., Vos S., Wahlund L.O., Wallin A., Westwood S., Zetterberg H., Lovestone S., Morgan B.P.

Collaborateur⸱rice⸱s

NIMA Consortium, Annex: NIMA-Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease

Contributeur⸱rice⸱s

Bullmore E.T., Bhatti J., Chamberlain S.J., Correia M.M., Crofts A.L., Dickinson A., Foster A.C., Kitzbichler M.G., Knight C., Lynall M.E., Maurice C., O'Donnell C., Pointon L.J., St George Hyslop P., Turner L., Vertes P., Widmer B., Williams G.B., Morgan B.P., Leckey C.A., Morgan A.R., O'Hagan C., Touchard S., Cavanagh J., Deith C., Farmer S., McClean J., McColl A., McPherson A., Scouller P., Sutherland M., Boddeke HWGM, Richardson J.C., Khan S., Murphy P., Parker C.A., Patel J., Jones D., de Boer P., Kemp J., Drevets W.C., Nye J.S., Wittenberg G., Isaac J., Bhattacharya A., Carruthers N., Kolb H., Pariante C.M., Turkheimer F., Barker G.J., Byrom H., Cash D., Cattaneo A., Gee A., Hastings C., Mariani N., McLaughlin A., Mondelli V., Nettis M., Nikkheslat N., Randall K., Sheridan H., Simmons C., Singh N., Van Loo V., Vicente-Rodriguez M., Wood T.C., Worrell C., Zajkowska Z., Plath N., Egebjerg J., Eriksson H., Gastambide F., Adams K.H., Jeggo R., Thomsen C., Pederson J.T., Campbell B., Möller T., Nelson B., Zorn S., O'Connor J., Attenburrow M.J., Baird A., Benjamin J., Clare S., Cowen P., Huang I.D., Hurley S., Jones H., Lovestone S., Mada F., Nevado-Holgado A., Oladejo A., Ribe E., Smith K., Vyas A., Hughes Z., Balice-Gordon R., Duerr J., Piro J.R., Sporn J., Perry V.H., Cleal M., Fryatt G., Gomez-Nicola D., Mancuso R., Reynolds R., Harrison N.A., Cercignani M., Clarke C.L., Hoskins E., Kohn C., Murray R., Wilcock L., Wlazly D., Mount H.

ISSN

1552-5279 (Electronic)

ISSN-L

1552-5260

Statut éditorial

Publié

Date de publication

06/2019

Peer-reviewed

Oui

Volume

Numéro

Pages

776-787

Langue

anglais

Notes

Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Résumé

Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.
A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.
Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).
Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Mots-clé

Aged, Alzheimer Disease/blood, Alzheimer Disease/diagnosis, Amyloid beta-Peptides/blood, Biomarkers/blood, Cognitive Dysfunction/blood, Cognitive Dysfunction/diagnosis, Cohort Studies, Complement Factor B, Complement Factor H, Humans, Inflammation, Internationality, Prognosis, Alzheimer's disease, Biomarker, Complement, Plasma

URN

urn:nbn:ch:serval-BIB_E5F2C092E3542

OAI-PMH

oai:serval.unil.ch:BIB_E5F2C092E354

DOI

10.1016/j.jalz.2019.03.007

Pubmed

31047856

Web of science

000470084500005

Open Access

Oui